Internal Medicine, Rheumatology · Somerset, KY
NPI
1447478029
Since 2007
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
26 Oxford Way, Suite C
Somerset, KY, 42503
Phone (606) 802-2300
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
137,108 services
Medicare patients, 2024
759
Average age 72
Drug cost, 2024
$8.4M
2,923 prescriptions
Company payments, 2025
$2,147
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Timothy A Lonesky was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 54,000 times for 56 patients. In total Timothy A Lonesky billed 137,108 services in 58 codes, and Medicare paid $1.6M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-29.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 54,000 | 56 | $3.61 | $195K |
| J3262 Injection, tocilizumab, 1 mg | Office | 33,925 | 31 | $4.41 | $150K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 15,950 | 107 | $33.38 | $532K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 10,550 | 39 | $9.18 | $97K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 6,510 | 19 | $8.57 | $56K |
| J0897 Injection, denosumab, 1 mg | Office | 2,281 | 38 | $20.46 | $47K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 2,084 | 20 | $20.54 | $43K |
| 86235 Immunoassay | Office | 1,485 | 179 | $17.27 | $26K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 1,420 | 26 | $0.09 | $134 |
| 99214 Office E&M - Established | Office | 528 | 326 | $87.90 | $46K |
| 96372 Injection Administration | Office | 368 | 122 | $10.73 | $3,950 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 350 | 11 | $0.23 | $79.67 |
| 83516 Immunoassay | Office | 295 | 154 | $11.25 | $3,318 |
| 96365 Intravenous Infusion, Hydration | Office | 274 | 144 | $45.09 | $12K |
| 99204 Office E&M - New | Office | 234 | 234 | $108.33 | $25K |
By year: 2022 $6.1M for 522,563 services; 2023 $1.9M for 141,169 services; 2024 $1.6M for 137,108 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 86235 Immunoassay | 1,485 | 179 | $17.27 | $26K |
| 83516 Immunoassay | 295 | 154 | $11.25 | $3,318 |
| 86431 Immunoassay | 187 | 184 | $5.51 | $1,031 |
| 86200 Immunoassay | 187 | 185 | $12.52 | $2,341 |
| 86226 Immunoassay | 184 | 183 | $11.71 | $2,154 |
| 86225 Immunoassay | 174 | 173 | $13.33 | $2,319 |
| 86038 Immunoassay | 174 | 173 | $11.68 | $2,031 |
| 86481 Immunoassay | 160 | 158 | $97.49 | $16K |
| 83520 Immunoassay | 148 | 81 | $16.63 | $2,461 |
| 82306 Clinical Chemistry | 145 | 143 | $28.66 | $4,156 |
Medicare prescription drug claims, 2024
In 2024, the drug Timothy A Lonesky prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 323 prescriptions and refills. In total Timothy A Lonesky wrote 2,923 Medicare prescriptions that cost $8.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 323 | 750 | 163 | $13K |
| Methotrexate Methotrexate Sodium | 299 | 550 | 133 | $5,635 |
| Prednisone Generic | 289 | 476 | 159 | $2,000 |
| Orencia Clickject Abatacept | 178 | 178 | 33 | $1.1M |
| Rinvoq Upadacitinib | 175 | 179 | 29 | $1.2M |
| Enbrel Sureclick Etanercept | 136 | 158 | 26 | $1.2M |
| Humira(Cf) Pen Adalimumab | 117 | 121 | 29 | $835K |
| Leflunomide Generic | 100 | 220 | 47 | $6,219 |
| Xeljanz Xr Tofacitinib Citrate | 90 | 92 | 18 | $541K |
| Celecoxib Generic | 71 | 148 | 40 | $1,627 |
| Meloxicam Generic | 62 | 126 | 22 | $408 |
| Prolia Denosumab | 59 | 348 | 44 | $104K |
| Otezla Apremilast | 57 | 61 | Under 11 | $295K |
| Actemra Actpen Tocilizumab | 48 | 53 | Under 11 | $151K |
| Benlysta Belimumab | 42 | 42 | Under 11 | $203K |
Brand drugs: - claims; generic drugs: 1,630 claims; opioid claims: 39.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Timothy A Lonesky $2,147 ($2,147 in general payments such as food, travel and fees) from 18 companies. The largest payer was Amgen Inc. with $581.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 45 | $581 |
| E.R. Squibb & Sons, L.L.C. BMY | 17 | $224 |
| AstraZeneca Pharmaceuticals LP AZN | 10 | $224 |
| UCB, Inc. UCB.BR | 9 | $198 |
| Abbvie Inc. ABBV | 11 | $190 |
| Sobi, Inc SOBI.ST | 2 | $165 |
| Janssen Biotech, Inc. JNJ | 6 | $163 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $88.34 |
| GlaxoSmithKline, LLC. GSK | 4 | $85.1 |
| Pfizer Inc. PFE | 4 | $58.66 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.